SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-093527
Filing Date
2021-07-19
Accepted
2021-07-19 17:11:34
Documents
13
Period of Report
2021-07-19
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2122512d1_8k.htm   iXBRL 8-K 36850
2 CERTIFICATE OF AMENDMENT tm2122512d1_ex3-1.htm EX-3.1 8581
  Complete submission text file 0001104659-21-093527.txt   226217

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vyne-20210719.xsd EX-101.SCH 3051
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20210719_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20210719_pre.xml EX-101.PRE 22376
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2122512d1_8k_htm.xml XML 3819
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 211098601
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences